KRAS and melanoma: This is further confirmed by the analysis of YAP levels in human tumor specimens collected from patients with NSCLC and melanoma encoding BRAF V600E mutations, NSCLC patients with KRAS mutations, and NSCLC patients with wild-type BRAF and KRAS [76].